Critical Care Pharmaceutical Markets: A Strategic Analysis
This report focuses on the specific needs and market applications of the critical care pharmaceuticals market, the options presented by the market, the factors associated with strategic market development, and prospects for the future.
The major indications for critical care are discussed as well as the range of pharmaceutical products used in the critical care environment. The strategic market characteristics of the critical care pharmaceuticals market are also discussed. The trends —- cost-containment programs, restricted formulary acceptance, clinical pharmacy, and the growth of the generic drug population —- as well as their impacts on the clinical care pharmaceutical markets are discussed. These are selected to assess the rationale for intentionally targeting the critical care pharmaceuticals market in hospitals alone and as part of an overall hospital pharmaceutical marketing strategy. They are presented to provide the most informative picture of potential market in this field.
This report covers current the critical care pharmaceutical market in a broad sense. It does not go into the details of specific products, companies, or technologies as they are used in the hospital clinical care setting except as general classes.
Market analysis for this report is limited in the sense of projections, market shares, etc. Instead, it considers the various aspects of past market development and estimates within the overall hospital market. It looks at the development of the market in terms of the existing, realistic market potential. This is tempered by discussions of where and how these markets may develop and the factors influencing them. This report does not discuss in detail the individual products that may be marketed in each of the critical care segments/facilities (e.g., cardiology, neurology, infectious diseases, etc). Some mention is made of indications and facilities by way of explaining the market environment, but greater emphasis is placed on the product classes, in their generic sense, and their application to critical care environment and its issues.
The focus of the report is on the strategic factors associated with existing and future market potentials to provide pharmaceutical companies wishing to enter the field with a “field general’s” perspective.
The analysis presented in this report is based on data from a combination of company, government, industry, institutional, and private sources. It includes information from extensive literature reviews, as well as interviews and discussions with experts in the field, including healthcare policy analysts, criticalists (MDs), critical care nurses, pharmacy experts, other medical professionals, and pharmaceutical business development managers.
Table of Contents
CHAPTER One: Executive Summary
- Overview
- Market Factors and Challenges
- Market Summary
- Scope and Methodology
CHAPTER Two: Background and Basics
- Critical Care Overview
- Settings and Features
- Types of Intensive Care
- Medical/Surgical/Respiratory ICU
- Coronary Care Units (CCU)
- Neurological ICU
- Trauma / Burn ICU
- Neonatal Intensive Care Unit (NICU)
- Critical Care Conditions
- General Conditions
- Neonatal ICU Conditions
- General Problems of Prematurity
- Anemia
- Apnea
- Bradycardia
- Bronchopulmonary Dysplasia (BPD)
- Hydrocephalus
- Intraventricular Hemorrhage (IVH)
- Jaundice/Hyperbilirubinemia
- Necrotizing Enterocolitis (NEC)
- Patent Ductus Arteriosus (PDA)
- Periventricular Leukomalacia (PVL)
- Respiratory Distress Syndrome (RDS)
- Retinopathy of Prematurity (ROP)
- Sepsis
- Transient Tachypnea of the Newborn (TTN)
- Adult ICU Conditions
- Abdominal Aortic Aneurysm (AAA)
- Acquired Immune Deficiency Syndrome (AIDS)
- Acute Respiratory Distress Syndrome (ARDS)
- Anemia
- Angina Pectoris
- Aspiration
- Asthma
- Brain Aneurysm
- Cardiomyopathy
- Chronic Obstructive Pulmonary Disease (COPD)
- Collapsed Lung (Pneumothorax)
- Coma
- Congestive Heart Failure (CHF)
- Delirium (ICU psychosis/sundowning)
- Diabetes Mellitus
- Diarrhea
- Dysrhythmia (Arrhythmia) or Abnormal Heart Pattern
- Empyema
- Esophageal Varices
- Gastrointestinal (GI) Bleeding
- Heart Attack (Myocardial Infarction)
- Hemothorax
- Kidney (Renal) Failure
- Liver Failure (Cirrhosis)
- Drug Overdose
- Pancreatitis
- Pleural Effusion
- Pneumonia
- Pulmonary embolism
- Seizure Disorders (Epilepsy)
- Sepsis
- Shock
- Stroke (brain attack; cerebrovascular accident)
- Transient Ischemic Attack (TIA)
- Organ/Bone Marrow Transplantation
- Traumatic Brain Injury (TBI)
CHAPTER Three: Critical Care PharmaceuticalsClinical Pharmacy in Critical Care— Outcomes and Economics
- ICU Drug Summaries
- Antifungal Agents
- Antianxiety Drugs
- Antidelirium Agents
- Antidepressants
- Antibiotics
- Steroidal Anti-Inflammatory Drugs
- Nonsteroidal Anti-inflammatory Drugs
- Antiemetic Drugs
- Analgesics
- Anticonvulsants
- Inotropes
- Antidysrhythmic Drugs
- Antihypertension Drugs
- ACE Inhibitors
- Beta Blockers
- Calcium Channel Blockers
- Vasodilators
- Vasopressors
- Thrombolytic Drugs
- Anticoagulants
- Bronchodilators
- Diuretics
- Histamine (H-2) Receptor Antagonists
- Cytoprotective Agents
- Proton Pump Inhibitors
- Neuromuscular Blocking Drugs
Chapter Four: Market Considerations
- Pharmaceutical Market Context
- Factors in Forecasting the Critical Care Market
- Factors Affecting Growth
- Generics
- Critical Care Pharmacists
- Restricted Formularies
- Pricing
chapter Five: Strategic Considerations
List of Exhibits
CHAPTER One: Executive Summary
- Figure 1-1: The Estimated U.S. Market for Ethical Pharmaceuticals in the Critical Care Setting 1997-2005
CHAPTER Three: Critical Care Pharmaceuticals
- Table 3-1: Antifungal Agents
- Table 3-2: Antianxiety Agents
- Table 3-3: Antidelirium Agents
- Table 3-4: Antidepressants
- Table 3-5: Antibiotics
- Table 3-6: Steroidal Anti-inflammatory Agents
- Table 3-7: Nonsteroidal Anti-inflammatory Agents
- Table 3-8: Antiemetic Agents
- Table 3-9: Analgesic Agents
- Table 3-10: Anticonvulsant Agents
- Table 3-11: Inotropic Agents
- Table 3-12: Antidysrhythmic Agents
- Table 3-13: Antihypertensive Agents
- Table 3-14: Vasopressor Agents
- Table 3-15: Thrombolytic Agents
- Table 3-16: Anticoagulant Agents
- Table 3-17: Bronchodilator Agents
- Table 3-18: Diuretic Agents
- Table 3-19: Histamine (H-2) Receptor Antagonist Agents
- Table 3-20: Cytoprotective Agents
- Table 3-21: Proton Pump Inhibitor Agents
- Table 3-22: Neuromuscular Blocking Agents
Chapter Four: Market Considerations
- Figure 4-1: The Market for Ethical Pharmaceuticals in the United States1997-2005
- Figure 4-2: Growth in the Market for Ethical Pharmaceuticals in the United States 1997-2005
- Figure 4-3: The Estimated U.S. Market for Ethical Pharmaceuticals in the Critical Care Setting 1997—2005
- Figure 4-4: Medicare and Medicaid Hospital Admission Trends: 1990-2001
- Figure 4-5: Medicare and Medicaid Hospital Admission Trends by Percentage: 1990-2001
- Table 4-1: Pharmaceuticals Coming Off-Patent in 2006
Other users found this report page using the following search terms: Critical Care sepsis icu ccu scbu special care indiacardiologymarketpharma
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.